






Morpholinyl derivatives of doxorubicin and process for their preparation.**BEST AVAILABLE COPY**

Patent number: EP0434960
Publication date: 1991-07-03
Inventor: BARGIOTTI ALBERTO (IT); FAIARDI DANIELA (IT); GRANDI MARIA (IT); SUARATO ANTONINO (IT)
Applicant: ERBA CARLO SPA (IT)
Classification:
- international: A61K31/71; C07C43/313; C07H15/252
- european: C07H15/252D; C07C43/313
Application number: EP19900121905 19901115
Priority number(s): GB19890028654 19891219;
GB19900007513 19900403

Also published as:

 WO9109046 (A1)
 IE904543 (A1)
 EP0434960 (B1)
 SK278994B (B6)
 PT96226 (B)

more >>

Cited documents:

 GB2172594
 EP0188293
 US4374980

Abstract of EP0434960

Morpholinyl derivatives of doxorubicin having the general formula A:

<CHEM>

wherein X represents a linear or branched C1-c6 alkyl group or a benzyl group - CH₂C₆H₅, and having (S) or (R) configuration at carbon atom C-2" of the morpholino ring, are antitumor agents.

Data supplied from the esp@cenet database - Worldwide

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 434 960 A1

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 90121905.5

(51) Int. Cl.⁵: **C07H 15/252**, **A61K 31/71**,
C07C 43/313

(22) Date of filing: 15.11.90

(30) Priority: 19.12.89 GB 8928654
03.04.90 GB 9007513

(43) Date of publication of application:
03.07.91 Bulletin 91/27

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI NL SE

(71) Applicant: **FARMITALIA CARLO ERBA S.r.L.**
Via Carlo Imbonati 24
I-20159 Milano(IT)

(72) Inventor: **Falardi, Daniela**
Via Bernardo Da Pavia, 6
I-27100 Pavia(IT)

Inventor: **Barglotti, Alberto**
Via Donati, 8
I-20100 Milan(IT)


Inventor: **Grandi, Maria**
Piazza 5 Giornate, 6
I-20100 Milan(IT)

Inventor: **Suarato, Antonino**
Via Degli Imbriani, 39
I-20158 Milan(IT)

(74) Representative: **Glambrocono, Alfonso, Dr.**
Ing. et al
Ing. A. Glambrocono & C. S.r.l. Via Rosolino
Pilo 19/B
I-20129 Milano(IT)

(84) Morpholinyl derivatives of doxorubicin and process for their preparation.

(57) Morpholinyl derivatives of doxorubicin having the general formula A:



A

EP 0 434 960 A1

wherein X represents a linear or branched C₁-C₆ alkyl group or a benzyl group -CH₂C₆H₅, and having (S) or (R)

configuration at carbon atom C-2" of the morpholino ring, are antitumor agents.

MORPHOLINYL DERIVATIVES OF DOXORUBICIN AND PROCESS FOR THEIR PREPARATION

The invention relates to anthracycline glycosides, to processes for their preparation and to pharmaceutical compositions containing them.


The invention provides new anthracycline glycosides of general formula A in which the 3'-nitrogen atom is enclosed in a 2-alkoxy-4-morpholinyl ring:

5

10

15

20

A

wherein X represents a linear or branched C₁-C₆ alkyl group or a benzyl residue -CH₂C₆H₅, and pharmaceutically acceptable acid addition salts thereof. The preferred salt is the hydrochloride salt.

Morpholino-anthracyclines are well known compounds endowed with promising antitumor activity on experimental murine tumors [see: E.W. Acton in Bioactive Molecules, 55-101, vol 6, Edited by J.W. Lown, Elviseiser 1988]. Among these, 2-methoxy-4-morpholinyl anthracyclines (X = OCH₃) have been already claimed in our patent US-A-4,672,075. These compounds were prepared through a reductive-alkylating process using a chiral-dihyaldehyde. In the present invention, on the other hand, the substituted morpholinyl rings are prepared through bis-alkylation of the 3'-amino group of anthracyclines with novel chiral 1,5-diiido-2-alkoxy or -benzyloxy derivatives that are within the scope of the invention.

The preferred anthracycline glycosides of general formula A include:


- A1: 3'-deamino-3'-(2"(S)-benzyloxy-4"-morpholinyl)-doxorubicin (X = CH₂C₆H₅),
- A2: 3'-deamino-3'-(2"(S)-ethoxy-4"-morpholinyl)-doxorubicin (X = C₂H₅),
- A3: 3'-deamino-3'-(2"(R)-isopropoxy-4"-morpholinyl)-doxorubicin (X = CH(CH₃)₂),
- A4: 3'-deamino-3'-(2"(S)-methoxy-4"-morpholinyl)-doxorubicin (X = CH₃)
- A5: 3'-deamino-3'-(2"(R)-methoxy-4"-morpholinyl)-doxorubicin (X = CH₃)

and their hydrochloride salts. The compounds may have a (S) or (R) configuration at carbon atom C-2" of the morpholino ring.

The new anthracycline glycoside antibiotics of the invention, i.e. those of general formula A, are prepared by the formation of a substituted morpholinyl ring at C-3' on the sugar moiety of the antitumor anthracycline glycoside doxorubicin (B):


45

50



The present invention therefore provides a process for the preparation of an anthracycline glycoside of formula A or a pharmaceutically acceptable acid addition salt thereof, which process comprises:

(i) reacting doxorubicin or an acid addition salt thereof, for example the hydrochloride salt, with a diiodo compound of general formula C:




wherein X is as defined above; and

(ii) if desired, converting the anthracycline glycoside of formula A thus obtained into a pharmaceutically acceptable acid addition salt thereof.


The alkylation of the C-3' amino group of doxorubicin or the doxorubicin salt is typically performed in step (i) in a polar aprotic solvent and in the presence of a dry organic base such as triethylamine. Reaction is generally carried out at room temperature from eight to twenty four hours. The carbon atom C-2 bearing the -OX group in the diiodo compound may have a (S) or (R) configuration. In a preferred embodiment, doxorubicin or its hydrochloride, dissolved in a polar aprotic solvent is reacted, at room temperature and in the presence of a dry organic base, with the diiodo compound of general formula C to give the corresponding morpholinyl doxorubicin derivative of formula A which, after purification on a silica gel column using as eluting system methylene chloride-methanol (97:5 v/v), is isolated, by treatment with methanolic anhydrous hydrogen chloride, as its hydrochloride.

The invention also provides a process for the preparation of optically pure diiodo compounds C, starting from sugar precursors such as the compound of general formula S derived from L-arabinose:




wherein X is as defined above. This process comprises:


(a) subjecting to periodate oxidation a compound of formula S :



- 10 wherein X is as defined above;
 (b) reducing the thus-obtained dialdehyde derivative of formula D :



- 20 wherein X is as defined above;
 (c) sulfonating the thus-obtained dihydroxy derivative of formula E :



- 30 wherein X is as defined above; and
 (d) iodinating the sulfonated derivative thus obtained.




In order to prepare the diiodo compounds C, 1-substituted sugars S, prepared following standard procedures described in "Methods on Carbohydrate Chemistry" Acad. Press., Vol 1, (1962), are first transformed into dialdehyde derivatives D. Generally, D- or L-arabinose is employed as a starting material. This is reacted with an alcohol X-OH thereby to form the compound of formula S. The dialdehyde derivatives can be obtained by using periodate oxidation in water, then reduced to 1,5-dihydroxy-2-alkoxy or -benzyloxy-3-oxa-pentane E by using reducing agents such as sodium borohydride or sodium cyanoborohydride at pH 6.5 in a mixture of water and methanol.

40 The resultant dihydro compounds E are sulfonated at the 1- and 5-hydroxyl groups, typically by using p-toluenesulfonyl chloride in pyridine at 4°C to give the sulfonyl esters of formula F from which the diiodo derivatives C are obtained upon treatment with sodium or potassium iodide in aprotic solvent such as methylethylketone at 85°C from one to two days. The sequence of these reactions do not affect the chirality at C-2 of the diiodo derivatives C which is the same of the starting sugars S.

45 A preferred embodiment of a process according to the invention is illustrated by the following reaction Scheme:

50

55

Reaction SchemeL-arabinoseTs=O₂S-C₆H₄-pCH₃

The present invention also provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier or diluent and, as active ingredient, an anthracycline glycoside of formula A or a pharmaceutically acceptable acid addition salt thereof. Conventional carriers or diluents may be used. The composition may be formulated and administered, for example intravenously, in conventional manner.

The anthracycline glycosides of formula A and pharmaceutically acceptable acid addition salts thereof are antitumour agents. They may be used to treat a patient with a tumour by administration of a therapeutically effective amount thereof. The compounds can be used to inhibit the growth of a tumour and are non-toxic at therapeutic doses.

The following Examples illustrate the invention.

Example 1

Preparation of 1,5-di(p-toluensulphonyl)oxy-2(s)-benzyloxy-3-oxa-pentane (F1)

L-arabinose (3 g, 0.022 mole) and benzyl alcohol (15 ml) were heated under stirring in presence of Dowex 50Wx2 (2 g) in acidic form. After four hours, the mixture was cooled and filtered. The solvent was removed under reduced pressure and 1-benzyl- β -L-arabinopyranoside (S1, 3.5 g) was recovered from acetone. TLC on Kieselgel Plate F₂₅₄ (Merck), eluting system methylene chloride/methanol/water (120/20/2 by volume) R_f=0.47. $[\alpha]_D^{25} = +215^\circ$ (c=1% water).

1-benzyl- β -L-arabinopyranoside (S1, 3.48 g; 0.0145 mole) was dissolved in water (100 ml) and treated with sodium periodate (5.6 g, 0.026 mole) at 0 °C for two hours. Then barium chloride was added and the mixture was brought to pH 7 with barium carbonate, filtered off and washed with water. The aqueous solution was concentrated under reduced pressure to a syrup and extracted with acetonitrile (50 ml). The organic phase was diluted with a mixture of methanol (20 ml) and water (10 ml) and treated with sodium cyanoborohydride (0.3 g) dissolved in water (5 ml). After 15 minutes the mixture was brought to pH 7 by adding Dowex 50Wx2 and filtered. The solvents were removed under reduced pressure to give 1,5-dihydroxy-2(S)-benzyloxy-3-oxa-pentane (E1, 2.6g, yield 85%). TLC on Kieselgel Plate-F₂₅₄ (Merck), eluting system methylene chloride/methanol (10/1 by volume) R_f=0.28. Compound E1 (2.6 g) was dissolved in dry pyridine and added with p-toluensulfonylchloride (6.67 g). The mixture was kept at 0 °C overnight, then poured into ice-water and extracted with methylene chloride. The organic phase was washed with water, separated off, dried over anhydrous sodium sulphate and filtered off. The solvent was removed under reduced pressure to afford 1,5-di(p-toluensulphonyl)oxy-2(S)-benzyloxy 3-oxa-pentane (F1, 4.3 g, yield 68%). TLC on Kieselgel Plate F₂₅₄ (Merck), eluting system methylene chloride/acetone (98/2 by volume) R_f=0.55

¹HNMR (CDCl₃, 400 MHz) δ : 2.42 (s, 6H, two CH₃TS); 3.65, 3.69 (two dt, J=4.7, 11.7Hz, 2H, TsOCH₂CH₂O); 3.94 (two, dd, J=5.3, 10.5Hz, 2H, OCH₂CH₂OTs); 4.08 (t, J=4.7Hz, 2H, Ts-O-CH₂CH₂-O); 4.46, 4.56 (two, d, J=11.7Hz, 2H, OCH₂-Ph); 4.72 (t, J=5.3Hz, 1H, O-CH₂-CH₂-OTs); 7.2-7.8 (m, 13H, aromatics).

Example 2

Preparation of 1,5-diiodo-2(S)-benzyloxy-3-oxa-pentane (C1).

Compound F1 (4.3 g, 8.3 mmole), prepared as described in Example 1, was dissolved in methylethylketone (50 ml) and added with sodium iodide (7.4 g, 49 mmole). The mixture was kept at 95 °C for twentyfour hours. After that, the solvent was removed under reduced pressure and the residue was extracted with n-hexane. The organic phase was concentrated to a syrup to give the title compound C1 (3.5 g, yield 90%). TIC on Kieselgel Plate F₂₅₄ (Merck), eluting system n-hexane/ ethyl acetate (10/0.5 by volume) R_f=0.34

¹HNMR (CDCl₃, 400 MHz) δ : 3.27 (t, J=6.8Hz, 2H, J-CH₂CH₂-O); 3.30 (d, J=5.5Hz, 2H, O-CH-CH₂-J); 3.84 (m, 2H, J-CH₂CH₂-O); 4.63, 4.74 (two d, J=11.7Hz, 2H, O-CH₂Ph); 4.81 (t, J=5.5Hz, 1H, O-CH-CH₂-J); 7.3-7.5 (m, 5H, aromatics).

Example 3

Preparation of 3'-deamino-3-[2(S)-benzyloxy-4-morpholinyl] doxorubicin (A1)

To a solution of doxorubicin hydrochloride (0.5 g, 0.86 mmole) in dry dimethylformamide (20 ml) was added 1,5-diiodo-2(S)-benzyloxy-3-oxa-pentane (C1, 3.5 g, 7.54 mmole) and dry triethylamine (3.6 ml, 2.6 mmole). The mixture was kept at room temperature for 36 hours, then was poured in water and extracted with methylene chloride. After standard work-up, the crude product was purified on silicic acid column using as eluting system a mixture of methylene chloride/methanol (97/5 by volume), to give, after treatment with methanolic anhydrous hydrogen chloride, the title compound A1 (0.3 g, yield 46%) as hydrochloride salt. TLC on Kieselgel Plate F₂₅₄ (Merck), eluting system methylene chloride/methanol (10/1 by volume) R_f = 0.6. FD-MS: m/e 756 (M⁺)

¹HNMR of free base (CDCl₃, 200 MHz) δ:

1.37 (d, J=6.6Hz, 3H, 5'-CH₃); 1.76 (m, 2H, 2'-CH₂); 2.14 (dd, J=3g, 14.8Hz, 1H, 8ax-H); 2.2-2.7 (m, 6H, CH₂-N-CH₂, 8eq-H, 3'-H); 3.00 (d, J=18.8Hz, 1H, 10ax-H); 3.55, 4.00 (two m, 2N, O-CH₂-CH₂N); 3.68 (s, 1H, 4'-H); 3.94 (q, J=6.6Hz, 1H, 5'-H); 4.08 (s, 3H, OCH₃); 4.51, 4.77 (two d, J=12.1Hz, 2H, OCH₂Ph); 4.65 (dd, J=2.6, 4.0Hz, 1H, OCH(OCH₂Ph)CH₂N); 4.71 (s, 1H, COCH₂OH); 5.28 (dd, J=2.4, 3.8Hz, 1H, 7-H); 5.54 (m, 1H, 1'-H); 7.2-8.1 (m, 8H, aromatic H's); 13.22 (s, 1H, 11-OH); 13.95 (s, 1H, 6-OH).

Example 4

Preparation of 1,5-diiodo-2(S)-ethoxy-3-oxa-pentane (C2).

The title compound C2 was prepared starting from L-arabinose (3 g) following sequential reactions as described in Example 1 and Example 2.

1-ethyl-α-L-arabinopyranoside (S2): [α]_D²⁰ = +233.5° (c=1% water)

1,5-dihydroxy-2(S)-ethoxy-3-oxa-pentane (E2): TLC on Kieselgel Plate F₂₅₄ (Merck) eluting system methylene chloride/methanol (10/1 by volume) R_f = 0.33.

1,5-di(p-toluensulphonyl)oxy-2(S)-ethoxy-3-oxa-pentane (F2):

TLC on Kieselgel Plate F₂₅₄ (Merck), eluting system methylene chloride/acetone (98/2 by volume) R_f = 0.56

¹HNMR (CDCl₃, 200MHz) δ:

1.11 (t, J=7.0Hz, 3H, OCH₂CH₃); 2.43 (s, 6H, two CH₃-Ts); 3.44, 3.58 (two dq, J=7.0, 9.4Hz, 2H, OCH₂CH₃); 3.68 (m, 2H, O-CH₂-CH₂-OTs); 3.89 (d, J=5.4, 2H, o-CH-CH₂-OTs); 4.10 (t, J=4.8Hz, 2H, OCH₂-CH₂OTs); 4.61 (t, J=5.4Hz, 1H, O-CH-CH₂OTs); 7.3-7.8 (m, 8H, aromatic H's).

1,5-diiodo-2(S)-ethoxy-3-oxa-pentane (C2):

TLC on Kieselgel Plate F₂₅₄ (Merck), eluting system n-hexane/ethyl acetate (10/0.5 by volume) R_f = 0.37

¹HNMR (CDCl₃, 200MHz) δ:

1.24 (t, 7.0Hz, 3N, OCH₂CH₃); 3.23 (d, J=5.6Hz, 2H, J-CH₂CH-O); 3.27 (t, J=6.8Hz, 2H, J-CH₂CH₂-O); 3.58, 3.77 (two dq, J=7.0, 9.3Hz, 2H, OCH₂CH₃); 3.78, 3.87 (two dt, J=6.8, 10.6Hz, 2H, J-CH₂CH₂-O); 4.70 (t, J=5.6Hz, 1H, O-CH-CH₂-J).

Example 5

Preparation of 3'-deamino-3'[(2(S)-ethoxy-4-morpholinyl)] doxorubicin (A2)

Doxorubicin hydrochloride (0.5 g) was reacted with compound C2 (3 g) following the same procedure reported in Example 3 to give the title compound A2 (0.28 g) as hydrochloride salt.

TLC on Kieselgel Plate F₂₅₄ (Merck), eluting system methylene chloride/methanol (10/1 by volume) R_f = 0.58

FD-MS: m/e 694 (M⁺)

¹HNMR as free base (CDCl₃, 200MHz) δ:

1.16 (t, J=7.0Hz, 3H, OCH₂CH₃); 1.36 (d, J=6.4Hz, 3H, 5'-CH₃); 1.7-1.8 (m, 2H, 2'-CH₂); 2.16 (dd, J=4.1, 14.7Hz, 1H, 8ax-H); 2.3-2.6 (m, 6H, CH₂-N-CH₂); 8eq-H, 3'-H); 3.02 (d, J=18.8Hz, 1H, 10ax-H); 3.26 (dd, 1.9, 18.8Hz, 1H, 10eq-H); 3.46, 3.75 (two dq, J=7.0, 9.8Hz, 2H, OCH₂CH₃); 3.53, 3.93 (two m, 2H, OCH₂CH₂N); 3.68 (s, 1H, 4'-H); 3.93 (q, J=6.4Hz, 1H, 5'-H); 4.08 (s, 3H, OCH₃); 4.56 (dd, J=2.3, 4.7Hz, 1H, OCH(OCH₂CH₃)CH₂N); 4.72 (s, 1H, 9-OH); 4.74 (s, 2H, COCH₂OH); 5.30 (m, 1H, 7-H); 5.55 (m, 1H, 1'-H); 7.3-8.1 (m, 3H, aromatic H's); 13.25 (s, 1H, 11-OH); 13.97 (s, 1H, 6-OH)

Example 6

Preparation of 1-5-diiodo-2(R)-isopropoxy-3-oxa-pentane (C3)

The title compound C3 was prepared starting from L-arabinose (3 g) following sequential reactions as described in Example 1 and Example 2.

1-isopropyl- β -L-arabinopyranoside (S3): $[\alpha]_D = +225^\circ$ (water)

1,5-dihydroxy-2(R)-isopropoxy-3-oxa-pentane (E3):

- 5 TLC on Kieselgel Plate F₂₅₄ (Merck), eluting system methylene chloride/methanol (10/1 by volume) $R_f = 0.36$

1,5-di(p-toluensulphonyl)oxy-2(R)-isopropoxy-3-oxa-pentane (F3)

TLC on Kieselgel Plate F₂₅₄ (Merck), eluting system methylene chloride/acetone (95/2 by volume) $R_f = 0.55$

¹HNMR (CDCl₃, 200MHz) δ :

- 10 1.05, 1.10 (two d, J=6.2Hz, 6H, CH(CH₃)₂); 2.42 two s, 6H, CH₃-Ts; 3.64 (two m, 2H, Ts-O-CH₂CH₂-O); 3.76 (m, 1H, CH(CH₃)₂); 3.84 (m, 2H, O-CH-CH₂-OTs); 4.08 (t, J=5.6Hz, 2H, Ts-O-CH₂CH₂-O); 7.3-7.8 (m, 8H, aromatic H's).

1,5-diiodo-2(R)-isopropoxy-3-oxa-pentane (C3)

TLC on Kieselgel Plate F₂₅₄ (Merck), eluting system n-hexane/ethyl acetate (10/0.5 by volume) $R_f = 0.40$

- 15 ¹HNMR (CDCl₃, 200MHz) δ :

1.20, 1.22 (two d, J=6.4Hz, 6H, CH(CH₃)₂); 3.24 (d, J=5.6Hz, 2H, O-CH-CH₂-J); 3.28 (t, J=6.7Hz, 2H, J-CH₂CH₂-O); 3.6-3.8 (m, 2H, J-CH₂CH₂-O); 3.94 (m, 1H, CH(CH₃)₂); 4.76 (t, J=5.6Hz, 1H, O-CH-CH₂-J).

Example 7

20

Preparation of 3'-deamino-3-[2(R)-isopropoxy-4-morpholinyl] doxorubicin (A3)

Doxorubicin hydrochloride (0.5 g) was reacted with compound C3 (3.2 g) following the same procedure reported in Example 3 to give the title compound A3 (0.21 g) as hydrochloride salt.

- 25 TLC on Kieselgel Plate F₂₅₄ (Merck), eluting system methylene chloride/methanol (10/1 by volume) $R_f = 0.55$

FD-MS: m/e 708 (M⁺)

¹HNMR as free base (CDCl₃, 200MHz) δ :

- 30 1.09, 1.16 (two d, J=6.0Hz, 6H, CH(CH₃)₂); 1.36 (d, J=6.6Hz, 3H, 5'-CH₃); 1.80 (m, 2H, 2'-CH₂); 2.15 (dd, J=4.0, 14.9Hz, 1H, 8ax-H); 2.3-2.8 (m, 6H, CH₂NCH₂, 8eq-H, 3'-H); 2.97 (d, J=18.8Hz, 1H, 10ax-H); 3.26 (d, J=18.8Hz, 1H, 10eq-H); 3.54 (m, 1H, O-CH(H)CH₂N); 3.74 (s, 1H, 4'-H); 3.81-4.1 (m, 3H, OCH(H)CH₂N, 5'-H, OCH(CH₃)₂); 4.08 (s, 3H, OCH₃); 4.66 (s, 1H, 9-OH); 4.68 (dd, J=2.2, 4.9Hz, 1H, OCH(OCH(CH₃)₂)-CH₂N); 4.75 (s, 2H, COCH₂OH); 5.28 (m, 1H, 7-H); 5.55 (m, 1H, 1'-H); 7.3-7.8 (m, 3H, aromatic H's); 13.24 (s, 1H, 11-OH); 13.97 (s, 1H, 6-OH).

35

Example 8

1,5-dihydroxy-2(S)-methoxy-3-oxa-pentane (E4)

- 40 1,5-dioxo-2(S)-methoxy-3-oxa-pentane (D4) (1.5 g, 11mmole), prepared as described in "Methods on Carbohydrate Chemistry" Acad.Press., Vol.1, 445, (1962), was dissolved in a mixture of water (10 ml) and methanol (10 ml) and treated with sodiumborohydride (0.1 g) dissolved in water (2 ml). After 20 minutes the solution was brought to pH 7 with an acidic resin Dowex 50WX2, filtered off and the solvent was removed under reduced pressure to give 1.4 g (Yield 93%) of the title compound TLC on Kieselgel Plate F₂₅₄ -
- 45 (Merck), eluting system methylene chloride:methanol (10:1 by volume) brown spot at $R_f = 0.24$ after heating the TLC plate previously sprayed with sulfuric acid.

¹HNMR (200 MHz, DMSO-d₆) δ :

- 3.26 (s, 3H, OCH₃); 3.4-3.6 (m, 6H, -CH₂-CH₂-O-CH-CH₂-); 4.37 (t, J=5.4 Hz, 1H, O-CH-O); 4.40 (bm, 2H, HO-CH₂CH₂, CH₂CH₂-OH)

50

Example 9

1,5-di(p-toluensulfonyl)oxy-2(S)-methoxy-3-oxa-pentane (F4)

- 55 1,5-dihydroxy-2(S)-methoxy-3-oxa-pentane (E4) (1.4 g, 10.3 mmole), prepared as described in Example 8, was dissolved in dry pyridine (10 ml) and treated at 0°C with p-toluensulfonylchloride (6.4 g, 0.034 mole). The mixture was kept at 4°C overnight, then was poured into an ice-water mixture and finally extracted with methylene chloride. The organic phase was washed with water, separated off, dried over

anhydrous sodium sulphate, filtered off. The solvent was removed under reduced pressure. The crude material, was chromatographed on a silicic acid column using methylene chloride as eluting agent to give 2.8 g (yield 62%) of pure title derivative,

- TLC on Kieselgel Plate F₂₅₄ (Merck), eluting system methylene chloride:acetone (95:5 by volume) brown spot at R_f=0.55 after heating the TLC plate previously sprayed with sulfuric acid.

¹HNMR (200 MHz, CDCl₃) δ:

2.44 (s, 6H, CH₃-Ph); 3.27 (s, 3H, OCH₃); 3.69 (m, 2H, SO₂OCH₂CH₂-O); 3.90 (m, 2H, SO₂OCH₂-CH-O); 4.11 (m, 2H, SO₂OCH₂CH₂-O); 4.56 (t, J=5.3Hz, 1H, O-CH-CH₂); 7.3-7.8 (m, 8H, aromatic H's).

10 Example 10

Preparation of 1,5-diiodo-2(S)-methoxy-3-oxa-pentane (C4)

- 1,5-di(p-toluensulfonyl)oxy-2(S)-methoxy-3-oxa-pentane (F4) (1.6 g, 3.6 mmole), prepared as described in Example 9, was dissolved in methylethylketone (30 ml) and treated with sodium iodide (3.04 g, 20.2 mmole) at 85° C for two days. After that, the solvent was removed in vacuo and the residue was added with n-hexane (50 ml) and water. The organic phase was separated off, dried over anhydrous sodium sulphate, filtered off. The solvent was removed under reduced pressure to give 1,5-diiodo-2(S)-methoxy-3-oxa-pentane (C4) (1.2 g, yield 86%). TLC on Kieselgel Plate F₂₅₄ (Merck), eluting system methylene chloride, brown spot at R_f=0.54 after heating the TLC plate previously sprayed with sulfuric acid.

¹HNMR (200 MHz, CDCl₃) δ:

3.15 (m, 4H, J-CH₂CH₂-OCH-CH₂-J); 3.40 (s, 3H, OCH₃); 3.80 (m, 2H, J-CH₂CH₂-O); 4.62 (t, J=5.6 Hz, 1H, O-CH-CH₂).

25 Example 11

Preparation of 3'-deamino-[2"(S)-methoxy-4"-morpholinyl]-doxorubicin (A4)

- To a solution of doxorubicin hydrochloride (80 mg, 0.138 mmole) dissolved in dry dimethylformamide (4 ml) was added 1,5-diiodo-2(S)-methoxy-3-oxa-pentane (C4 , 0.8 g, 2.06 mmole) and triethylamine (0.056 ml, 0.388 mmole). The reaction mixture was kept at room temperature under stirring for 36 hrs, then was poured in water and extracted with methylene chloride. After standard work up, the crude product was purified on silicic acid column using as eluting system amixture of methylene chloride methanol (97.5 : 2.5 by volume), to give, after treatment with methanolic anhydrous hydrogen chloride, 40 mg (yield 45%) of the title compound as hydrochloride salt. TLC on Kieselgel Plate F₂₅₄ (Merck), eluting system methylene chloride:methanol (19:1 by volume) R_f=0.15

Free base: ¹HNMR (400 MHz, CDCl₃) δ:

- 13.98 (s, 1H, 6-OH); 13.27 (s, 1H, 11-OH); 8.03 (dd, J=1.1, 7.7Hz, 1H, 1-H); 7.78 (dd, J=7.7, 8.6Hz, 1H, 2-H); 7.39 (dd, J=1.1, 8.6Hz, 1H, 3-H); 5.55 (m, 1H, 1'-H); 5.30 (dd, J=2.1, 4.1Hz, 1H, 7-H); 4.74 (d, J=4.5Hz, 14-CH₂OH); 4.74 (s, 1H, 9-OH); 4.49 [dd, J=2.6, 4.1Hz, 1H, NCH₂-CH(OCH₃)O]; 4.08 (s, 3H, 4-OCH₃); 3.94 (q, J=6.6Hz, 1H, 5'-H); 3.93 [m, 1H, NCH₂CH(H)O]; 3.67 (m, 1H, 4'-H); 3.54 [m, 1H, NCH₂CH(H)O]; 3.38 [s, 3H, NCH₂CH-OCH₃]; 3.27 (dd, J=19, 18.8Hz, 1H, 10-Heq); 3.04 (d, J=18.8Hz, 1H, 10-Hax); 3.00 (t, J=4.5Hz, 1H, CH₂OH); 2.60 [dd, J=4.1, 11.4Hz, 1H, NCH(H)CHOCH₃]; 2.6-2.5 (m, 3H, NCH(H)-CHOCH₃, NCH₂CH₂O); 2.4-2.3 (m, 2H, 8-Heq, 3'-H); 2.15 (dd, J=4.1, 14.7Hz, 8-Hax); 1.76 (m, 2H, 2'-CH₂); 1.26 (d, J=6.6Hz, 3H, 5'-CH₃).

Example 12

Preparation of 1,5-dihydroxy-2(R)-methoxy-3-oxa-pentane (E5)

- The title compound was prepared as described in Example 8 starting from 1,5-dioxo-2(R)-methoxy-3-oxa-pentane (D5) which in turn can be prepared as described in "Methods on Carbohydrate Chemistry" Acad.Press., Vol.1, 445, (1962). TLC on Kieselgel Plate F₂₅₄ (Merck), eluting system methylene chloride:methanol, brown spot at R_f=0.24 after heating the TLC plate previously sprayed with sulfuric acid.

55

Example 13

Preparation of 1,5-di(p-toluensulfonyl)oxy-2(R)-methoxy-3-oxa-pentane (F5)

1,5-dihydroxy-2(R)-methoxy-3-oxa-pentane (E5), prepared as describe in Example 12, was transformed into the title compound F5 following the same procedure reported in Example 9. TLC on Kieselgel Plate F₂₅₄ (Merck), eluting system methylene chloride:acetone (95:5 by volume) brown spot at R_f=0.55 after heating the TLC plate previously sprayed with sulfuric acid.

5

Example 14

Preparation of 1,5-diiodo-2-(R)-methoxy-3-oxa-pentane (C5)

10 1,5-di(p-toluensulfonyl)oxy-2(R)-methoxy-3-oxa-pentane (F5), prepared as described in Example 13, was converted into the diiodo derivative C5 following the procedure described in Example 10. TIC on Kieselgel Plate F₂₅₄ (Merck), eluting methylene chloride, system brown spot at R_f=0.54 after heating the TLC plate previously sprayed with sulfuric acid.

15 Example 15

Preparation of 3'-deamino-[2'(R)-methoxy-4"-morpholinyl]-doxorubicin (A5)

The title compound was prepared by condensing doxorubicin hydrochloride with 1,5-diiodo-2(R)-methoxy-3-oxa-pentane (C5) , prepared as above described, following the procedure reported in Example 11.

TLC on Kieselgel Plate F₂₅₄ (Merck), eluting system methylene chloride:methanol (19:1 by volume) R_f=0.13

Free base: ¹HNMR (400 ,MHz, CDCl₃) δ:

25 13.97 (s, 1H, 6-OH); 13.25 (s, 1H, 11-OH); 8.03 (dd, J=1.1, 7.7Hz, 1H, 1-H); 7.78 (dd, J=7.6, 7.7Hz, 1H, 2-H); 7.39 (dd, J=1.1, 7.6Hz, 1H, 3-H); 5.53 (d, J=3.4Hz, 1H, 1'-H); 5.29 (dd, J=2.5, 4.1Hz, 1H, 7-H); 4.75 (s, 2H, 14-CH₂OH); 4.71 (s, 1H, 9-OH); 4.46 [dd, J=2.6, 4.7Hz, 1H, NCH₂-CH(OCH₃)O]; 4.08 (s, 3H, 4-OCH₃); 3.93 (q, J=6.6Hz, 1H, 5'-H); 3.92 [m, 1H, NCH₂CH(H)O]; 3.70 (m, 1H, 4'-H); 3.56 [m, 1H, NCH₂CH(H)O]; 3.40. [s, 3H, NCH₂CH-OCH₃]; 3.26 (dd, J=19, 19.9Hz, 1H, 10-Heq); 3.03 (d, J=19.9Hz, 1H, 10-Hax); 2.66 [dd, J=2.6, 11.4Hz, 1H, NCH(H)CHOCH₃]; 2.53 (m, 1H, NCH(H)CH₂O); 2.5-2.3 (m, 4H, NCH(H)CH₂O, NCH(H)CHOCH₃, 8-Heq, 3'H); 2.15 (dd, J=4.1, 14.7Hz, 8-Hax); 1.8-1.7 (m, 2H, 2'-CH₂); 1.36 (d, J=6.6Hz, 3H, 5'-CH₃).

35 BIOLOGICAL ACTIVITY OF 3'-deamino-[2"(S)-methoxy-4"-morpholinyl]doxorubicin (A4) and 3'-deamino-[2"(R)-methoxy-4"-morpholinyl]doxorubicin (A5).

The compounds have been tested in several experimental system in order to ascertain their cytotoxicity and antitumor activity in experimental animals in comparison with parent Doxorubicin. The new anthracyclines result more cytotoxic than the parent drug on LoVo and LoVo Doxorubicin-resistant cell line (LoVo/Dx), Table 1, and are active "in vivo" against doxorubicin-resistant cell lines.

40 The primary screening "in vivo" was carried out in BDF1 mice bearing P388 Doxorubicin-resistant Johnson's leukemia (P388/Dx) (10⁵ cell/mouse). The drugs were administered iv on day 1 after tumor inoculation. Results are reported in Table 2. Both compounds were active and more potent than Doxorubicin.

45 Compound A4 has also been tested on Doxorubicin-resistant P388 Schabel "in vitro", Table 3, and "in vivo" on BDF1 mice (10⁶ cell/mouse), treatment iv on day 1 after the tumor inoculation, Table 4. Finally, compound Ia has been studied on solid tumor such as mammary murine and human carcinoma (MX1) with iv and oral route, Table 5 and 6.

50

55

Table 1

5 Colony assay test against LoVo and LoVo/Dx resistant cells
"in vitro" (treatment for 4 hrs)

10	Compound	LoVo (IC ₅₀ =ng/ml) ^a	LoVo/Dx (IC ₅₀ =ng/ml) ^a	R.I. ^b
15	Doxorubicin	48.8	2553	52.6
	A4	8.7	31.7	3.6
	A5	6.5	40.1	6.1

- 20 a) IC₅₀ = concentration inhibiting 50% of colony growth
b) R.I. = Resistance Index = (IC₅₀ LoVo/Dx)/(IC₅₀ LoVo)

25

Table 2

30 Effect of A4 and A5 on Doxorubicin-resistant P388 Johnson's
35 Leukemia "in vivo".

40	Compound	O.D. ^c (mg/kg)	T/C ^d %
	Doxorubicin	13	86
	A4	0.09	250
45	A5	0.13	244

- 50 c) O.D. = Optimal Dose: maximally tolerated dose.
d) T/C% = Median survival time of treated mice over median
survival time of controls x 100.

55

Table 3

5 Effect of A4 on sensitive and Doxorubicin-resistant P388
 10 Leukemia (Schabel) "in vitro" (treatment 1 hr).

Compound	P388	P388/Dx
	(IC ₅₀ ng/ml) ^a	(IC ₅₀ ng/ml) ^a
Doxorubicin	52.7	4000
15 A4	7.6	24.3

20 c) IC₅₀ = concentration inhibiting 50% of cellular survival.

Table 4

25 Effect of A4. on Doxorubicin-resistant P388 Schabel's
 30 Leukemia "in vivo".

Compound	O.D. ^a	T/C ^d
	(mg/kg)	%
Doxorubicin	13	100
35 A4	0.09	153

Table 5

Effect of A4 on murine mammary carcinoma.

5

Compound	Route and Treatment Schedule	O.D. ^a (mg/kg)	Tumor Inhibition
			%
Doxorubicin	iv q4dx4 ^e	5.85	99
A4	iv q4dx4	0.065	94
	po q4dx4 ^g	0.1	97

10

15

f) iv q4dx4 = treatment iv every four days for four times

20

g) po q4dx4 = oral treatment every four days for four times

25

Table 6

Effect of A4 on mammary human carcinoma (MX1).

30

Compound	Route and Treatment Schedule	O.D. ^a (mg/kg)	Tumor Inhibition
			%
Doxorubicin	iv q7dx3 ^h	6	72
A4	iv q7dx3	0.05	98
	po q7dx3 ⁱ	0.13	99

35

40

h) iv q7dx3 = treatment iv every seven days for three times

45


i) po q7dx3 = oral treatment every seven days for three times

Claims

50


1. An anthracycline glycoside of general formula A:

55

A

wherein X represents a linear or branched C₁-C₆ alkyl group or a benzyl group, and pharmaceutically acceptable acid addition salts thereof.

2. A compound according to claim 1, which is 3'-deamino-3'-[2''(S)-benzyloxy-4''-morpholinyl]-doxorubicin or its hydrochloride.
3. A compound according to claim 1, which is 3'-deamino-3'-[2''(S)-ethoxy-4''-morpholinyl]-doxorubicin or its hydrochloride.
4. A compound according to claim 1, which is 3'-deamino-3'-[2''(R)-isopropoxy-4''-morpholinyl]-doxorubicin or its hydrochloride.
5. A compound according to claim 1, which is 3'-deamino-3'-[2''(S)-methoxy-4''-morpholinyl]-doxorubicin or its hydrochloride.
6. A compound according to claim 1, which is 3'-deamino-3'-[2''(R)-methoxy-4''-morpholinyl]-doxorubicin or its hydrochloride.
7. A process for preparing an anthracycline glycoside of formula A as defined in claim 1, or a pharmaceutically acceptable salt thereof, which process comprises:
 - (i) reacting doxorubicin or an acid addition salt thereof with a diiodo compound of formula C:

C

wherein X is as defined in claim 1; and

(ii) if desired, converting the anthracycline glycoside of formula A thus obtained into a pharmaceutically acceptable acid addition salt thereof.

8. A process according to claim 7, wherein doxorubicin or its hydrochloride, dissolved in a polar aprotic

solvent is reacted, at room temperature and in the presence of a dry organic base, with the diiodo compound of general formula C to give the corresponding morpholinyl doxorubicin derivative of formula A which, after purification on a silica gel column using as eluting system methylene chloride-methanol (97:5 v/v), is isolated, by treatment with methanolic anhydrous hydrogen chloride, as its hydrochloride.

5

9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and, as active ingredient, an anthracycline glycoside of formula A as defined in claim 1 or a pharmaceutically acceptable acid addition salt thereof.

10

10. An anthracycline glycoside of formula A as defined in claim 1, or a pharmaceutically acceptable acid addition salt thereof, for use as an antitumor agent.


11. A diiodo compound of formula C as defined in claim 7.

15

12. A process for the preparation of a diiodo compound of formula C as defined in claim 7, which process comprises:

(a) subjecting to periodate oxidation a compound of formula S :

20




25

wherein X is as defined in claim 1;

(b) reducing the thus-obtained dialdehyde derivative of formula D :

30




35

wherein X is as defined above;

40

(c) sulfonating the thus-obtained dihydroxy derivative of formula E :

45



50

wherein X is as defined above; and

(d) iodinating the sulfonated derivative thus obtained.

55


13. A process according to claim 12, wherein D- or L-arabinose is reacted with an alcohol X-OH, wherein X is as defined in claim 1, thereby to form the compound of formula S.

14. A process according to claim 12, wherein the dihydroxy derivative of formula E is reacted with p-toluenesulfonyl chloride in step (c).

15. A process for the preparation of an anthracycline glycoside of formula A as defined in claim 1 or a pharmaceutically acceptable salt thereof, said process being substantially as hereinbefore described in any one of Examples 3, 5, 7, 11 and 15.
16. A process for the preparation of a diiodo compound of formula C as defined in claim 7, said process being substantially as hereinbefore described in any one of Examples 2, 4, 6, 10 and 14.

Claims for the following Contracting States: ES, GR


1. A process for preparing an anthracycline glycoside of formula A



A

wherein X represents a linear or branched C₁-C₆ alkyl group or a benzyl group, and pharmaceutically acceptable acid addition salts thereof, which process comprises:

- (i) reacting doxorubicin or an acid addition salt thereof with a diiodo compound of formula C:



C

wherein X is as defined in claim 1; and


- (ii) if desired, converting the anthracycline glycoside of formula A thus obtained into a pharmaceutically acceptable acid addition salt thereof.

2. A process according to claim 1, wherein doxorubicin or its hydrochloride, dissolved in a polar aprotic solvent is reacted, at room temperature and in the presence of a dry organic base, with the diiodo compound of general formula C to give the corresponding morpholinyl doxorubicin derivative of formula A which, after purification on a silica gel column using as eluting system methylene chloride-methanol (97:5 v/v), is isolated, by treatment with methanolic anhydrous hydrogen chloride, as its hydrochloride.
3. A process for the preparation of a diiodo compound of formula C as defined in claim 1, which process

comprises:

(a) subjecting to periodate oxidation a compound of formula S:

5




10

wherein X is as defined in claim 1;

15

(b) reducing the thus-obtained dialdehyde derivative of formula D:

20




25

wherein X is as defined above;

(c) sulfonating the thus-obtained dihydroxy derivative of formula E:

30



35

wherein X is as defined above; and

40

(d) iodinating the sulfonated derivative thus obtained.

4. A process according to claim 3, wherein D- or L-arabinose is reacted with an alcohol X-OH, wherein X is as defined in claim 1, thereby to form the compound of formula S.

45 5. A process according to claim 3, wherein the dihydroxy derivative of formula E is reacted with p-toluensulfonyl chloride in step (c).

50

55



European
Patent Office

EUROPEAN SEARCH REPORT

Application Number

EP 90 12 1905

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
X,Y	GB-A-2 172 594 (FARMITALIA) " Whole document "	1-11,15	C 07 H 15/252 A 61 K 31/71 C 07 C 43/313
Y	EP-A-0 188 293 (KIRIN) " Abstract; page 22, line 3 - page 23, line 31; page 40, line 5 - page 41, line 3 "	7,8,11,15	
Y	US-A-4 374 980 (H. UMEZAWA) " Whole document "	7,8,11,15	
			TECHNICAL FIELDS SEARCHED (Int. Cl.5)
			C 07 H 15/00 A 61 K 31/00 C 07 C 43/00
The present search report has been drawn up for all claims			
Place of search		Date of completion of search	Examiner
The Hague		21 March 91	BRENNAN J.
<div><div><p>CATEGORY OF CITED DOCUMENTS</p><p>X: particularly relevant if taken alone</p><p>Y: particularly relevant if combined with another document of the same category</p><p>A: technological background</p><p>O: non-written disclosure</p><p>P: intermediate document</p><p>T: theory or principle underlying the invention</p></div><div><p>E: earlier patent document, but published on, or after the filing date</p><p>D: document cited in the application</p><p>L: document cited for other reasons</p><p>&: member of the same patent family, corresponding document</p></div></div>			

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.